<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.wjso.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>World Journal of Surgical Oncology - Most accessed articles</title>
        <link>http://www.wjso.com</link>
        <description>The most accessed research articles published by World Journal of Surgical Oncology</description>
        <dc:date>2012-04-21T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.wjso.com/content/4/1/50" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/2/1/32" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/10/1/60" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/1/1/11" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/3/1/36" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/2/1/18" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/4/1/55" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/2/1/44" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/7/1/42" />
                                <rdf:li rdf:resource="http://www.wjso.com/content/7/1/11" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.wjso.com/content/4/1/50">
        <title>Low grade Endometrial Stromal Sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases</title>
        <description>Background:
Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new cases in the USA or Europe per year. The aim of this study was to evaluate the behavior of low-grade endometrial stromal sarcoma (LGESS) in relation to their clinical and pathological features and to identify possible prognostic factors.Patients and methodsFourteen patients with histologically proven ESS were included in the analysis. Endometrial stromal sarcoma is characterized by proliferations composed of cells with Endometrial stromal cell differentiation. Low-grade endometrial stromal sarcoma has an infiltrating margin and typically show extensive worm-like vessel invasion.
Results:
The median age was 44.35 &#177; 6 years. The most common presenting symptom was vaginal bleeding, occurring in twelve patients (86%). Diagnosis was made through Fractional dilatation and curettage in four patients (28.5%). Eight patients had a total abdominal hysterectomy and salpingo-ophorectomy (57%). Radiotherapy as adjuvant therapy was administered to four patients (28.5%). The median follow-up time was 45.6 months (range 24&#8211;84). The median overall survival of the 14 patients was 45.35 &#177; 21 months (range 20&#8211;83). Three of 14 patients demonstrated a recurrence of disease at 9, 72, and 96 months respectively. The recurrent diseases were treated with surgery, chemotherapy, and radiotherapy. No patient died of the disease. Clinico-pathological parameters did not significantly differ between patients with and without recurrence, but patients with no myometrial invasion and low mitotic count &lt;= 5/HPF showed longer disease-free survival.
Conclusion:
Five-year survival rate was 93%. Survival probabilities were calculated by the product limit method of Kaplan and Meier that showed, patients with no myometrial invasion and low mitotic count &lt;= 5/HPF have longer disease-free survival, but P value was not significant.</description>
        <link>http://www.wjso.com/content/4/1/50</link>
                <dc:creator>Tahereh Ganjoei</dc:creator>
                <dc:creator>Nadereh Behtash</dc:creator>
                <dc:creator>Mamak Shariat</dc:creator>
                <dc:creator>Azam Sadat Mousavi</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2006, null:50</dc:source>
        <dc:date>2006-08-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-4-50</dc:identifier>
                                <prism:require>/content/figures/1477-7819-4-50-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>50</prism:startingPage>
        <prism:publicationDate>2006-08-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/2/1/32">
        <title>Role of primary surgery in advanced ovarian cancer</title>
        <description>Background:
Major issues in surgery for advanced ovarian cancer remain unresolved. Existing treatment guidelines are supported by a few published reports and fewer prospective randomized clinical trials.
Methods:
We reviewed published reports on primary surgical treatment, surgical expertise, inadequate primary surgery/quality assurance, neoadjuvant chemotherapy, interval debulking, and surgical prognostic factors in advanced ovarian cancer to help resolve outstanding issues.
Results:
The aim of primary surgery is a well-planned and complete intervention with optimal staging and surgery. Surgical debulking is worthwhile as there are further effective treatments available to control unresectable residual disease. Patients of gynecologic oncology specialist surgeons have better survival rates. This may reflect a working &apos;culture&apos; rather than better technical skills. One major problem though, is that despite pleas to restrict surgery to experienced surgeons, specialist centers are often left to cope with the results of inadequate primary surgical resections. Patients with primary chemotherapy or those who have had suboptimal debulking may benefit from interval debulking. A proposal for a better classification of residual tumor is given.
Conclusions:
Optimal surgical interventions have definite role to play in advanced ovarian cancers. Improvements in surgical treatment in the general population will probably improve patients&apos; survival when coupled with improvements in current chemotherapeutic approaches.</description>
        <link>http://www.wjso.com/content/2/1/32</link>
                <dc:creator>Karsten Muenstedt</dc:creator>
                <dc:creator>Folker Franke</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2004, null:32</dc:source>
        <dc:date>2004-10-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-2-32</dc:identifier>
                                <prism:require>/content/figures/1477-7819-2-32-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>32</prism:startingPage>
        <prism:publicationDate>2004-10-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/10/1/60">
        <title>Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway</title>
        <description>Background:
The combined effects of anticancer drugs with nutritional factors against tumor cells have been reported previously. This study characterized the efficacy and possible mechanisms of the combination of sorafenib and vitamin K1 (VK1) on glioma cell lines.
Methods:
We examined the effects of sorafenib, VK1 or their combination on the proliferation and apoptosis of human malignant glioma cell lines (BT325 and U251) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, flow cytometry and 4&apos;,6-diamidino-2-phenylindole (DAPI) assay. The signaling pathway changes were detected by western blotting.
Results:
Sorafenib, as a single agent, showed antitumor activity in a dose-dependent manner in glioma cells, but the effects were more pronounced when used in combination with VK1 treatment. Sorafenib in combination with VK1 treatment produced marked potentiation of growth inhibition and apoptosis, and reduced expression of phospho-mitogen-activated protein kinase kinase (MEK) and phospho-extracellular signal-regulated kinase (ERK). Furthermore, the expression levels of antiapoptotic proteins Bcl-2 and Mcl-1 were significantly reduced.
Conclusions:
Our findings indicated that VK1 enhanced the cytotoxicity effect of sorafenib through inhibiting the Raf/MEK/ERK signaling pathway in glioma cells, and suggested that sorafenib in combination with VK1 maybe a new therapeutic option for patients with gliomas.</description>
        <link>http://www.wjso.com/content/10/1/60</link>
                <dc:creator>Wei Du</dc:creator>
                <dc:creator>Jing-ru Zhou</dc:creator>
                <dc:creator>Dong-liang Wang</dc:creator>
                <dc:creator>Kai Gong</dc:creator>
                <dc:creator>Qing-jun Zhang</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2012, null:60</dc:source>
        <dc:date>2012-04-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-10-60</dc:identifier>
                                <prism:require>/content/figures/1477-7819-10-60-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>60</prism:startingPage>
        <prism:publicationDate>2012-04-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/1/1/11">
        <title>Desmoid tumors of the abdominal wall: A case report</title>
        <description>Background:
Desmoid tumors are slow growing deep fibromatoses with aggressive infiltration of adjacent tissue but without any metastatic potential.Case PresentationWe report on two female patients with desmoid tumor of the abdominal wall who underwent primary resection. Both patients had a history of an earlier abdominal surgery. Preoperative evaluation included abdominal ultrasound, magnetic resonance imaging and computed tomography. The histology in both cases revealed a desmoid tumor.
Conclusion:
Complete surgical resection is the first line management of this tumor entity.</description>
        <link>http://www.wjso.com/content/1/1/11</link>
                <dc:creator>Marcus Overhaus</dc:creator>
                <dc:creator>Pan Decker</dc:creator>
                <dc:creator>Hans Fischer</dc:creator>
                <dc:creator>Hans Textor</dc:creator>
                <dc:creator>Andreas Hirner</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2003, null:11</dc:source>
        <dc:date>2003-07-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-1-11</dc:identifier>
                                <prism:require>/content/figures/1477-7819-1-11-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2003-07-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/3/1/36">
        <title>Goblet cell carcinoid of the appendix</title>
        <description>Background:
Goblet cell carcinoid (GCC) of the appendix is a rare neoplasm that share histological features of both adenocarcinoma and carcinoid tumor. While its malignant potential remains unclear, GCC&apos;s are more aggressive than conventional carcinoid. The clinical presentations of this neoplasm are also varied. This review summarizes the published literature on GCC of the appendix. The focus is on its diagnosis, histopathological aspects, clinical manifestations, and management.
Methods:
Published studies in the English language between 1966 to 2004 were identified through Medline keyword search utilizing terms &quot;goblet cell carcinoid,&quot; &quot;adenocarcinoid&quot;, &quot;mucinous carcinoid&quot; and &quot;crypt cell carcinoma&quot; of the appendix.
Results:
Based on the review of 57 published papers encompassing nearly 600 diagnosed patients, the mean age of presentation for GCC of the appendix was 58.89 years with equal representation in both males and females. Accurate diagnosis of this neoplasm requires astute observations within an acutely inflamed appendix as this neoplasm has a prominent pattern of submucosal growth and usually lacks the formation of a well-defined tumor mass. The mesoappendix was involved in 21.64% followed by perineural involvement in 2.06%. The most common clinical presentations in order of frequency were acute appendicitis in 22.5%; asymptomatic in 5.4%; non-localized abdominal pain in 5.15% and an appendicular mass in 3.09%. The most common surgical treatment of choice was appendectomy with right hemicolectomy in 34.70% followed by simple appendectomy in 24.57%. Concomitant distant metastasis at diagnosis was present in 11.16% of patients with the ovaries being the most common site in 3.60% followed by disseminated abdominal carcinomatosis in 1.03%. Local lymph node involvement was seen in 8.76% of patients at the time of diagnosis. The reported 5-year survival ranges from 60 % to 84%. GCC&apos;s of the appendix remains a neoplasm of unpredictable biological behavior and thus warrants lifelong surveillance for recurrence of the disease upon diagnosis and successful surgical extirpation.
Conclusion:
GCC of the appendix is a rare neoplasm. Due to its wide range of presentation, this tumor should be considered as a possible diagnosis in many varied situations leading to abdominal surgery. Histopathological features such as increased number of Paneth cells, increased amount of mucin secretion and presence of pancreatic polypeptide may predict a more aggressive behavior. The advocated plan of management recommended for patients with tumors that involve the adjacent caecum or with high-grade tumors with histological features such as an increased mitotic rate involve initial appendectomy with completion right hemicolectomy due to the high possibility of local recurrence with intraperitoneal seeding prior to lymph node involvement and a 20% risk of metastatic behavior. In female patients with GCC of the appendix regardless of age, bilateral salpingo-oophorectomy is advocated. In cases with obvious spread of the disease chemotherapy, mostly with 5-FU and leucovorin is advised. Cytoreductive surgery with adjuvant intraperitoneal chemotherapy can offer improved survival in cases with advanced peritoneal dissemination.</description>
        <link>http://www.wjso.com/content/3/1/36</link>
                <dc:creator>Payam Pahlavan</dc:creator>
                <dc:creator>Rani Kanthan</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2005, null:36</dc:source>
        <dc:date>2005-06-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-3-36</dc:identifier>
                                <prism:require>/content/figures/1477-7819-3-36-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2005-06-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/2/1/18">
        <title>Cutaneous horns: are these lesions as innocent as they seem to be?</title>
        <description>Background:
Cutaneous horns (cornu cutaneum) are uncommon lesions consisting of keratotic material resembling that of an animal horn. Cutaneous horn may arise from a wide range of the epidermal lesions, which may be benign, premalignant or malignant.Patients and methodsIn this respective study, we describe our experience of eleven patients with cutaneous horn treated at our centre between January 2000 and January 2004. The clinical, pathological and treatment details were extracted from the case records. Data is presented as frequency distribution.
Results:
There were 8 male and 3 female patients with a median age of 57 years. Most of the lesions were located on the ear, hand and scalp. Surgical resection was carried out in all the lesions. There were two cases of squamous cell carcinoma, and one case of basal cell carcinoma, other 8 cases were benign. None of the lesions recurred and no adjuvant treatment was given to any of the malignant lesions.
Conclusion:
Cutaneous horn is a clinical diagnosis that refers to a conical projection above the surface of the skin. The lesions typically occurs in sun exposed areas, particularly the face, ear, nose, forearms, and dorsum of hands. Even though our 60% of the cutaneous horns are benign possibility of skin cancer should always be kept in mind.</description>
        <link>http://www.wjso.com/content/2/1/18</link>
                <dc:creator>Eray Copcu</dc:creator>
                <dc:creator>Nazan Sivrioglu</dc:creator>
                <dc:creator>Nil Culhaci</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2004, null:18</dc:source>
        <dc:date>2004-06-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-2-18</dc:identifier>
                                <prism:require>/content/figures/1477-7819-2-18-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2004-06-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/4/1/55">
        <title>Malignant peripheral nerve sheath tumors (MPNST) - Clinicopathological study and treatment outcome of twenty-four cases</title>
        <description>Background:
Malignant peripheral nerve sheath tumor (MPNST) is biologically an aggressive tumor for which the treatment of choice is the surgery. We reviewed the clinical profile, diagnostic methods, treatment patterns, and outcome of twenty-four MPNST patients in this study.Patients and methodsA retrospective analysis of 24 MPNST patients, treated from 1994 to 2002, in the department of Surgical Oncology at All India Institute of Medical Sciences, New Delhi, was done. A combination of gross, histopathological and immunohistochemical findings, and proliferation markers (MIB1) were considered for diagnosis and grade of the MPNST. Survival analysis was done by the Kaplan-Meier method and differences were evaluated with the log-rank test. Multivariate analysis was carried out by using Cox&apos;s proportional hazards model by using SPSS (Version 9, Chicago, Illinois) software.
Results:
MPNST constituted 12% of all soft tissue sarcomas, where 21% (5/24) of patients had associated Von Recklinghausen&apos;s disease (VRHD). A higher incidence of male preponderance and multifocal MPNST were noted in the present series. At a mean follow-up of 38 months, 13 (54 %) patients had relapse of disease and 5-year over all and disease free survival were 58% and 35% respectively. In univariate analysis, sex (p = 0.05), tumor depth (p &lt; 0.03), and cellular differentiation (p &lt; 0.002) were shown to be adverse prognostic factors for disease free survival and sex (p = 0.04), cellular differentiation (p &lt; 0.0004), and tumor grade (p = 0.05) for overall survival. However, in multivariate analysis, cellular differentiation (p &lt; 0.005) and tumor grade (p &lt; 0.01) emerged as independent prognostic factors for both disease free and overall survival, respectively. Postoperative radiotherapy (RT) has shown a definite role in both disease free and overall survival in this study.
Conclusion:
MPNSTs constituted a significant proportion (12%) of soft tissue sarcoma in our medical center. Heterogeneous differentiation and multifocality of the tumor were few distinct features of MPNST. Sex and cellular differentiation were noticed as the new adverse prognostic factors and adjuvant radiotherapy has been proved to be a significant treatment tool in the current series.</description>
        <link>http://www.wjso.com/content/4/1/55</link>
                <dc:creator>Madhabananda Kar</dc:creator>
                <dc:creator>Suryanarayana Deo</dc:creator>
                <dc:creator>Nootan Shukla</dc:creator>
                <dc:creator>Ajay Malik</dc:creator>
                <dc:creator>Sidharth Datta Gupta</dc:creator>
                <dc:creator>Bidhu Mohanti</dc:creator>
                <dc:creator>Sanjay Thulkar</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2006, null:55</dc:source>
        <dc:date>2006-08-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-4-55</dc:identifier>
                                <prism:require>/content/figures/1477-7819-4-55-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>55</prism:startingPage>
        <prism:publicationDate>2006-08-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/2/1/44">
        <title>Seroma formation after surgery for breast cancer</title>
        <description>Background:
Seroma formation is the most frequent postoperative complication after breast cancer surgery. We carried out a study to investigate the effect of various demographic, clinical and therapeutic variables on seroma formation.Patients and methodsA retrospective cross sectional study of patients who underwent surgical therapy for breast cancer with either modified radical mastectomy (MRM) or breast preservation (BP) was carried out. The demographic data and clinical information were extracted from case records. Seroma formation was studied in relation to age, type of surgery, tumor size, nodal involvement, preoperative chemotherapy, surgical instrument (electrocautery or scalpel), use of pressure garment, and duration of drainage. The multiple logistic regression analysis was performed to estimate odds ratios.
Results:
A total of 158 patients with breast cancer were studied. The mean age of the patients was 46.3 years (SD &#177; 11.9). Seventy-three percent underwent modified radical mastectomy and the remaining 27% received breast preservation surgery. Seroma occurred in 35% of patients. In multivariate logistic regression analysis an association of postoperative seroma formation was noted with modified radical mastectomy (OR = 2.83, 95% CI 1.01&#8211;7.90, P = 0.04). No other factor studied was found to significantly effect the seroma formation after breast cancer surgery.
Conclusion:
The findings suggest that the type of surgery is a predicting factor for seroma formation in breast cancer patients.</description>
        <link>http://www.wjso.com/content/2/1/44</link>
                <dc:creator>Esmat Hashemi</dc:creator>
                <dc:creator>Ahmad Kaviani</dc:creator>
                <dc:creator>Masoume Najafi</dc:creator>
                <dc:creator>Mandana Ebrahimi</dc:creator>
                <dc:creator>Homeira Hooshmand</dc:creator>
                <dc:creator>Ali Montazeri</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2004, null:44</dc:source>
        <dc:date>2004-12-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-2-44</dc:identifier>
                                <prism:require>/content/figures/1477-7819-2-44-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>44</prism:startingPage>
        <prism:publicationDate>2004-12-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/7/1/42">
        <title>Myxoid liposarcoma:  a rare soft-tissue tumor with a misleading benign appearance</title>
        <description>Background:
Lipoma is by far the most common of all benign soft-tissue tumors which far outnumber malignant tumors. Soft-tissue sarcomas are malignant tumors and are usually named for the type of tissue in which they begin. Liposarcoma (LPS), which arises in the fatty tissue, is rather an uncommon soft-tissue tumor. Multiple histologic subtypes of liposarcoma are recognized, including myxoid liposarcoma, and correspond to tumors of very different prognosis. In two-third of the cases, this tumor occurs in the muscle while often demonstrating a misleading benign appearance as observed in the majority of soft-tissue sarcomas.Case presentationWe report the case of a 50-year-old man operated on for a fat tumor of the thigh initially diagnosed as lipoma but revealing to be a myxoid liposarcoma after histopathological examination. The initial incomplete tumor excision required the need for a re-excision with adjuvant chemotherapy and complementary radiotherapy.
Conclusion:
When any suspicious soft-tissue tumor is diagnosed, the combined information gathered from accurate preoperative radiographic planning and X-rays or surgical biopsy is of tremendous value for establishing the most appropriate therapeutic program, highly adapted to the histopathological findings.</description>
        <link>http://www.wjso.com/content/7/1/42</link>
                <dc:creator>Francois Loubignac</dc:creator>
                <dc:creator>Christophe Bourtoul</dc:creator>
                <dc:creator>Francoise Chapel</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2009, null:42</dc:source>
        <dc:date>2009-04-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-7-42</dc:identifier>
                                <prism:require>/content/figures/1477-7819-7-42-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>42</prism:startingPage>
        <prism:publicationDate>2009-04-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.wjso.com/content/7/1/11">
        <title>A comprehensive overview of radioguided surgery using gamma detection probe technology</title>
        <description>The concept of radioguided surgery, which was first developed some 60 years ago, involves the use of a radiation detection probe system for the intraoperative detection of radionuclides. The use of gamma detection probe technology in radioguided surgery has tremendously expanded and has evolved into what is now considered an established discipline within the practice of surgery, revolutionizing the surgical management of many malignancies, including breast cancer, melanoma, and colorectal cancer, as well as the surgical management of parathyroid disease. The impact of radioguided surgery on the surgical management of cancer patients includes providing vital and real-time information to the surgeon regarding the location and extent of disease, as well as regarding the assessment of surgical resection margins. Additionally, it has allowed the surgeon to minimize the surgical invasiveness of many diagnostic and therapeutic procedures, while still maintaining maximum benefit to the cancer patient. In the current review, we have attempted to comprehensively evaluate the history, technical aspects, and clinical applications of radioguided surgery using gamma detection probe technology.</description>
        <link>http://www.wjso.com/content/7/1/11</link>
                <dc:creator>Stephen Povoski</dc:creator>
                <dc:creator>Ryan Neff</dc:creator>
                <dc:creator>Cathy Mojzisik</dc:creator>
                <dc:creator>David O'Malley</dc:creator>
                <dc:creator>George Hinkle</dc:creator>
                <dc:creator>Nathan Hall</dc:creator>
                <dc:creator>Douglas Murrey</dc:creator>
                <dc:creator>Michael Knopp</dc:creator>
                <dc:creator>Edward Martin</dc:creator>
                <dc:source>World Journal of Surgical Oncology 2009, null:11</dc:source>
        <dc:date>2009-01-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7819-7-11</dc:identifier>
                                <prism:require>/content/figures/1477-7819-7-11-toc.gif</prism:require>
                <prism:publicationName>World Journal of Surgical Oncology</prism:publicationName>
        <prism:issn>1477-7819</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2009-01-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

